Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795085 | 0.82 | HSD11B1 (0.43) | HSD11B1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL4748008 | 0.80 | ALDH1A1 (0.44) | HSD11B1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL4792103 | 0.79 | HSD11B1 (0.40) | HSD11B1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL4792105 | 0.79 | HSD11B1 (0.40) | HSD11B1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL10289391 | 0.79 | KMT2A (0.42) | HSD11B1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL4748037 | 0.78 | KMT2A (0.43) | HSD11B1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL14405521 | 0.75 | KMT2A (0.37) | HSD11B1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL4748051 | 0.71 | KMT2A (0.40) | HSD11B1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL4748059 | 0.69 | KMT2A (0.38) | HSD11B1KMT2AGAA | |
| SCHEMBL4803238 | 0.68 | KMT2A (0.43) | HSD11B1KMT2AALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | HSD11B1 3535/4885KMT2A 2847/4885ALDH1A1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.